Elevated serum α-synuclein levels in huntington’s disease patients.

Elevated serum α-synuclein levels in huntington’s disease patients.

Publication date: Feb 08, 2020

Recent evidence suggests a potential role for mixed proteinopathies in the development of clinical manifestations in patients with Huntington’s disease (HD). A possible cross-talk between mutant huntingtin and ?-synuclein aggregates has been postulated. Serum ?-synuclein has been evaluated as a potential biomarker in patients with Parkinson’s disease. We presently sought to investigate serum ?-synuclein levels in 38 HD patients (34 symptomatic and 4 premanifest) and compare them to 36 controls. We found that ?-synuclein was elevated in HD patients vs. controls (2.49 +/- 1.47 vs. 1.40 +/- 1.16, p=0.001). There was no difference in ?-synuclein levels between symptomatic vs. premanifest HD, nor between HD patients receiving medication vs. treatment-na”ive. Furthermore, ?-synuclein levels showed no correlation with CAG2, Unified HD Rating Scale motor score, age, disease duration or disease burden score. Our results provide evidence for elevated serum ?-synuclein in HD and lend support to further investigating the role of ?-synuclein in this disorder.

Concepts Keywords
Biomarker Neuroscience
Correlation Parkin
Cross Huntingtin
Huntingtin Serum
Huntington Neuropathology
Mutant Synuclein
Nave Peripheral membrane proteins
Parkinson Disease
Serum Branches of biology


Type Source Name
disease MESH development


Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *